1 / 45

Part III Lessons from TGN1412

Part III Lessons from TGN1412. TGN1412. “A Watershed Incident” Fiona Godlee, Editor BMJ A line in the sand?. A cautionary tale from Waltham MA. Hell of human guinea pigs How the drug trial horror unfolded By MICHAEL SEAMARK, Daily Mail 17th March 2006. We saw human guinea pigs explode

cheyenne-mendez
Télécharger la présentation

Part III Lessons from TGN1412

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Part III Lessons from TGN1412

  2. TGN1412 “A Watershed Incident” Fiona Godlee, Editor BMJ A line in the sand? A cautionary tale from Waltham MA

  3. Hell of human guinea pigs How the drug trial horror unfolded By MICHAEL SEAMARK, Daily Mail 17th March 2006 We saw human guinea pigs explode Victims tearing at shirts By NICK PARKER, EMMA MORTON and JACQUI THORNTON 16th March 2006

  4. Peer Review • Wood AJ, Darbyshire J. Injury to research volunteers--the clinical-research nightmare.N Engl J Med. 2006 May 4;354(18):1869-71 • Ho MW, Cummins J. London Drug Trial Catastrophe – Collapse of Science and Ethics: Postmortem on the TGN1412 disaster Science in Society. 2006 Summer 30: 44-5

  5. SUN: A VOLUNTEER who escaped the drug test disaster told last night how he saw six healthy young men turn into wailing wrecks within minutes. Human guinea pig Raste Khan — who did not know he had been given a harmless placebo in the test — said it was like a horror film unfolding before his eyes.

  6. RASTE KHAN “The test ward turned into a living hell minutes after we were injected. The men went down like dominoes. First they began tearing their shirts off complaining of fever, then some screamed out that their heads felt like they were about to explode” “After that they started fainting, vomiting and writhing around in their beds” “It was terrifying because I kept expecting it to happen to me at any moment. But I felt fine and didn’t know why. An Asian guy next to me started screaming and his breathing went haywire as though he was having a terrible panic attack”

  7. RASTE KHAN “They put an oxygen mask on him but he kept tearing it off, shouting ‘Doctor, doctor, please help me!’ He started convulsing, shouting that he was getting shooting pains in his back.”

  8. TGN1412

  9. TGN 1412 CD28 T Cell Receptor SuperAgonist CD28 Humanised IgG4 Monoclonal Antibody

  10. TGN 1412 • By-passes Costimulation by Antigen Presenting Cell

  11. TGN 1412 • First Time in Man • Phase I March 13 2006 • 8 Subjects in first cohort • Healthy Male Volunteers • 2 Placebo • 6 Active • All 8 treated in rapid succession • Dose based on NOAEL • $4,000

  12. TGN 1412 No Observed Adverse Effect Level • Primates tested up to 50mg/kg (NOAEL) • Clinical testing started at 0.1mg/kg • 1/500 NOAEL • (NOAEL ≠ Pharmacologically effect) 0.3 – 5.0mg/kg

  13. TGN 1412 • Rapid onset • Cytokine Release Syndrome • Angioedema • Testing continued • Multiple Organ Failure • All subjects admitted to ICU • Prolonged immunosuppression • 1 still hospitalised, dry gangrene

  14. TGN 1412 Medicines and Healthcare Products Agency (MHRA) • Suspended CTA • Immediate Inquiry • Released • protocol, review and inquiry UK Government announces expert inquiry No review of ethical review to date

  15. TGN 1412 Expert Inquiry (Terms of Reference) • What may be necessary in transition from pre-clinical to first-in-man Phase 1 studies, specifically: • Biological molecules with novel mechanisms of action • New agents with highly species-specific action • New drugs for immune system targets • Interim report within 3 months (August) • Minutes of meetings and interim findings to be made public

  16. Lessons to be learnt from TGN 1412 (1) • Recruitment • Financial Incentives • Adequacy of Information • Choice of Subject in Phase I • Number of Subjects • Timing of Administration

  17. Lessons to be learnt from TGN 1412 (1) • Recruitment • Adequacy of Information • Consent • Choice of Subject in Phase I • Healthy volunteers • Number of Subjects • Timing of Administration

  18. Lessons to be learnt from TGN 1412 (2) • Sources of Information Reviewed • Regulatory Review • Ethical Review • Place of Independent Expert Review • Relevance of Preclinical Testing • Interspecies difference (Maccaca) • Transparency in Development • Publishing preclinical work • Transparency of Reviews • Response to Disasters

  19. Lessons to be learnt from TGN 1412 (3) • Caution in • developing immunomodulators • agonists • bypassing regulatory mechanisms (super) • Assumptions about Dose-Response • non-linear • bell shaped (optimum dose was 5mg/kg)

  20. Lessons to be learnt from TGN 1412 (4) • Homology may not mean affinity • Affinity may not translate downstream • Even monoclonals are not specific • Standards for preclinical testing

  21. Lessons to be learnt from TGN 1412 (4) The Immune System is a Capricious Pandora’s Box! Pandora 1898. John William Waterhouse British Pre-Raphaelite 1849-1917 Private collection Oil on canvas

  22. Lessons to be learnt from TGN 1412 (5) • Relationships with industry • Adequacy of training of staff • Adequacy of facilities • Adequacy of liability insurance Plan for the worst, hope for the best

  23. The Relevance of Animal Testing? Bhogal N, Combes R. TGN1412: time to change the paradigm for the testing of new pharmaceuticals.Altern Lab Anim. 2006 May;34(2):225-3 Fund for the Replacement of Animals in Medical Experiments

  24. The normal co-stimulatory mechanism of T-cell activation • TGN1412 recognises single CD28 on receptor Bhogal, Combes 2006

  25. CD28 monomer and corresponding TGN1412 binding epitope • 3-D model of CD28 extracellular domain • TGN1412 binding epitope circled Bhogal, Combes 2006

  26. Conservation of amino acid sequences of CD28. Substitution of Glutamate (E) in Macacca mulatta (Rhesus) for Glycine (G) in human, could have profound conformal implications, and hence affect affinity binding and downstream effects. Bhogal, Combes 2006

  27. The Relevance of Animal Testing • Need to establish validity • Staggered timing • Microdosing • Ex-vivo

  28. Learning from Mistakes • We have been assured repeatedly that proper procedures were followed, when the the real question is whether they were the right procedures. Goodyear M. BMJ March 25th 2006 • Nor will a collective claim of ‘not-guilty’ likely lead to understanding and correction Goodyear M. CMAJ In press

  29. "Is there any point to which you would wish to draw my attention?" "To the curious incident of the dog in the night-time." "The dog did nothing in the night-time." "That was the curious incident," remarked Sherlock Holmes. Conan-Doyle A. Silver Blaze 1892

  30. Part IV Moving Forward?

  31. Moving Forward? • Adaptation in a Changing World • Regulation and ethics always lags behind technology • Transparency • Governance • Support

  32. Moving Forward? • Transparency • One of the biggest threats to research integrity • Trust and confidence can only be restored by a guaranty of transparency

  33. Moving Forward? • Response to TGN1412 • This tragedy creates one more imperative for an open culture in medical research, a culture that many fear is increasingly losing its way Goodyear M. BMJ March 25th 2006 His call for a culture of greater openness in medical research is, I think, both powerful and timely Gunn A USA TODAY March 27th 2006 • Maximum transparency to reaffirm trust in clinical trials and their regulation. Commercial confidentiality should not obstruct independent scrutiny Lancet March 25th 2006

  34. Clinical trial registration: transparency is the watchword Sim I et al. May 20th 2006

  35. Opening Address to World Health Assembly, May 2005 "We are ready to move forward with an International Clinical Trials Registry. This will do much to strengthen the research process and its ability to win public trust" Dr Jong-wook Lee WHO Director-General died May 22 I Sim

  36. Restoring Normative Values Robert K Merton (1910-2003) CUDOS

  37. Moving Forward? • Adaptation in a Changing World • Regulation and ethics always lags behind technology • Transparency • Governance • Support

  38. Michael K Walsh, John J McNeil and Kerry J Breen Improving the governance of health research MJA 2005; 182: 468–471

  39. Summary • Research ethics has come a long way • In many ways it is unworkable, and unable to adapt • The whole scientific endeavour has come off the rails • Collaboration must replace competition • The process must be transparent and accountable • Responsible research is a collective culture

  40. A Fundamental Cultural Shift is required to move from Competition to Collaboration, and from Secrecy to Transparency, if we are to move forward and restore Normative Values to Science, and Ethical Integrity to Research

  41. Medical hubris...has overvalued the state of our knowledge and failed to acknowledge the extent of our ignorance McCormick J. Medical hubris and the public health: the ethical dimension. J Clin Epidemiol. 1996 49:619

More Related